A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors (clinicaltrials.gov) - Sep 22, 2025 - P1/2 | N=180 | Recruiting | Sponsor: Endeavor Biomedicines, Inc. | Initiation date: May 2025 ➔ Sep 2025
First-in-human • Trial initiation date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|